ON THE ISSUE OF STANDARDIZATION AND THE STUDY OF BIOPHARMACEUTICAL PROPERTIES OF ANTISPASMODIC TABLETS

Abstract

One of the main biopharmaceutical characteristics, which largely determines the bioequivalence of the drug, is the solubility of the drug substance, which determines the possibility of creating a dosage form with an effective dose of the drug, the kinetics of its release from the dosage form, the speed and completeness of absorption [1,4,6,7,9] . It is known from the literature that the solubility test, as a first approximation, characterizes the bioavailability of the drug, since in practice there is a very frequent correlation between the rate of dissolution and absorption [2,3]. The study of the bioavailability of drugs, preparations or their dosage forms usually begins with in vitro experiments, and ends with in vivo experiments with further research in a clinical setting. Dissolution studies in vitro experiments are relatively easy to use and represent an important tool for characterizing the biopharmaceutical quality of drugs. Dissolution testing in in vitro experiments is an important tool for characterizing the biopharmaceutical quality of drugs [5,8,10].